PRODH2 and neoplasm: They found that a targeted knock-in or the overexpression of PRODH2 encoding an enzyme in proline metabolism, which is an important metabolic process in T-cell effector activity, enhances the in vivo anti-tumor efficacy of CAR-T cells in multiple cancer models [128].